After genetic detection of a BRCA1/2 P/LP variant, carriers were faced with the decision to opt for a risk management option, with 48 (48.5%) women selecting RRM and 51 (51.5%) women selecting IBS. The gene discussed is BRCA1; the disease is irritable bowel syndrome.